Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins

Journal of Biomedical Science

Volumn 16, Issue 1, 2009, Pages

  Hajihassan, Zahra ^a   Rabbani Chadegani, Azra ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EDETIC ACID; HISTONE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ARTICLE; BINDING AFFINITY; CHROMATIN; CIRCULAR DICHROISM; DRUG DNA BINDING; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; FLUORESCENCE SPECTROSCOPY; GEL; GEL ELECTROPHORESIS; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY; ANIMAL; HUMAN; METABOLISM; PROTEIN BINDING; SPECTROFLUOROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; CIRCULAR DICHROISM; DNA; HISTONES; HUMANS; MITOXANTRONE; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE;

EID: 63149122886     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-16-31     Document Type: Article

References (33)

1. Mitoxantrone, cyclophosphamid and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. FA Holmes HY Yap L Esparza AU Buzdar GN Hortobaqui GR Blumenschein, Semin Oncol 1984 11 28 31 6385262
2. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma. WS Velasquez D Lew TM Grogan CH Spiridonidis SP Balcerzak SR Dakhil, J Clin Oncol 2003 21 1996 2003 10.1200/JCO.2003.09.047 12743154
3. Mitoxantrone in the treatment of acute myelogenous leukemia. X Thomas E Archimbaud, Hematol Cell Ther 1997 39 63 74 10.1007/s00282-997-0163-8 9352324
4. Development of mitoxantrone. RJ White FF Durr, Invest New Drugs 1985 3 85 93 10.1007/BF00174154 2410393
5. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. G Koutinos GP Stathopoulos I Dontas D Perrea-Kotsarolis E Couris PE Kararannacos, Anticancer Res 2002 22 815 20 12014656
6. Localization and molecular interaction of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis. A Feofano S Sharonov I Kudelina F Fleury I Nabiev, Biophys J 1997 73 3317 3327 9414242 10.1016/S0006-3495(97)78356-5
7. Characteristics of the binding of the anticancer agent's mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. JW Lown AR Morgen SF Yen YH Wang DW Wilson, Biochemistry 1985 24 4028 4035 10.1021/bi00336a034 4052381
8. Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly [d (G-C)].poly [d (G-C)], and poly [d (A-T)].poly [d (A-T)]. CR Krishnamoorthy Y Sau-Fong JC Smith JW Lown WD Wilson, Biochemistry 1986 25 5933 5940 10.1021/bi00368a015 3790495
9. Relationship between the pharmacological activity of antitumor drugs ametantrone and mitoxantrone (novatrone) and their ability to condense nucleic acids. J Kapuscinski Z Darzynkiewicz, Proc Nat Acad Sci USA 1986 83 6302 6306 3462696 10.1073/pnas.83.17.6302
10. Cellular uptake and inhibition of DNA synthesis by dihydroxy anthraquinone and two analogues. A Nishio EM Uveki, Cancer Res 1983 43 1951 1956 6339045
11. A comparison of DNA-binding drugs as inhibitors of E2F1 and SP1-DNA complexes and associated gene expression. SY Chiang JC Azizkhan TA Boorman, Biochemistry 1998 37 3109 3115 10.1021/bi9721142 9485464
12. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. G Capranico PD Isabella MB Tinelli F Zunino, Biochemistry 1993 32 3038 3046 10.1021/bi00063a015 8384486
13. Interaction of antitumor agent's ametantrone and mitoxantrone (novatrone) with double-stranded DNA. J Kapuscinski Z Darzynkiewicz, Biochm Pharmacol 1985 34 4203 4213 10.1016/0006-2952(85)90275-8
14. A molecular understanding of mitoxantrone-DNA adducts formation: effect of cytosine methylation and flanking sequence. BS Parker T Buley BJ Evison SM Cutts GM Neuman MN Iskander, J Biol Chem 2004 279 18814 18823 10.1074/jbc.M400931200 14963025
15. Interaction of anticancer drug mitoxantrone with DNA analyzed by electrochemical and spectroscopic methods. N Li Y Ma C Yang L Guo X Yang, Biophys Chem 2005 116 199 205 10.1016/j.bpc.2005.04.009 15893412
16. Chromatin structure and dynamics: A historical perspective in chromatin structure and dynamics: State of the art. EM Bradbury KE Van Holde, Elsevier, Amesterdam, The Netherlands, Zlatanova J, Leuba SH, 2004
17. Calcium-dependent priming of DNA synthesis in isolated rat liver nuclei. LA Burgoyne MA Waqar MR Atkinson, Biochem Biophys Res Commun 1970 39 254 259 10.1016/0006-291X(70)90786-2 5439512
18. Daunomycin-induced unfolding and aggregation of chromatin. A Rabbani M Iskander J Ausio, J Biol Chem 1999 274 18401 18406 10.1074/jbc.274.26.18401 10373446
19. Studies on histone: Preparative methods for histone fraction from calf thymus. EW Johns, Biochem J 1964 92 55 59 5840387
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. UK Laemmli, Nature 1970 227 680 685 10.1038/227680a0 5432063
21. In Molecular Cloning: A Laboratory Manual. J Sambrook EF Fritsch T Maniatis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y 1989
22. The attraction of proteins for small molecules and ions. G Scatchard, Ann N Y Acad Sci 1949 51 660 672 10.1111/j.1749-6632.1949.tb27297.x
23. Physical biochemistry, application to biochemistry and molecular biology. DM Freifelder, Freeman press, New York second 1982
24. Selective displacement of nuclear proteins by antitumor drugs having affinity for nucleic acids. J Bartkowiak J Kapuscinski MR Melamed Z Darzynkiewicz, Proc Natl Acad Sci USA 1989 86 5151 5154 2525781 10.1073/pnas.86.13.5151
25. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. LS Rosenberg MJ Carvlin TR Krugh, Biochemistry 1989 25 1002 1008 10.1021/bi00353a008
26. Affinity of anticancer drug daunomycin to core histones in solution: comparison of free and cross-liked proteins. A Rabbani S Abdosamadi N Sari-Saraf, Acta Pharmacol Sin 2007 28 731 737 10.1111/j.1745-7254.2007.00542.x 17439730
27. A comparison of the effect of anticancer drugs, idarubicin and adrimycin on soluble chromatin. Z Zahraei A Rabbani-Chadegani, Eur J Pharmacol 2007 575 28 33 10.1016/j.ejphar.2007.07.045 17716648
28. Mitoxantrone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. D Faulds JA Balfour P Chrisp HD Langtry, Drugs 1991 41 400 49 10.2165/00003495-199141030- 00007 1711446
29. Chromatin as a tool for study of genome functions in cancer. FD Umov, Ann N Y Acad Sci 2003 983 5 21 12724208
30. DNA sequence preferences for the anti-cancer drug mitoxantrone and related anthraquinones revealed by DNase I footprinting. KR Fox MJ Waring JR Brown S Neidle, FEBS Lett 1986 202 289 294 10.1016/0014-5793(86)80703-7 3720951
31. Binding of daunomycin to calf thymus nucleosomes. JB Chaires N Dattagupta DM Crothes, Biochemistry 1983 22 284 292 10.1021/bi00271a009 6824632
32. Chromatin organization and nuclear microenvironments in cancer cells. S He KL Dunn PS Espino B Drobic L Li J Yu JM Sun HY Chen S Pritchard JR Davie, J Cell Biochem 2008 104 2004 2015 10.1002/jcb.21485 17668423
33. Voltammetric behaviour of mitoxantrone at a DNA-biosensor. AM Oliveira Brett TRA Macedo D Raimundo MH Margues SHP Serrano, Biosensors Bioelectronics 1998 13 861 867 10.1016/S0956-5663(98)00053-0 9828383